Meeting
2022 ASCO Annual Meeting
Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
Authors
Qin Xu
Fujian Cancer Hospital, Fuzhou, China
Qin Xu , Chuan-ben Chen , Yang Sun , Zhangzhou Huang , Yibin Lin , Jing Liu , Li Li , Zirong Li , Junping Pan , Ying Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Cervical Cancer
Clinical Trial Registration Number
ChiCTR1900023015
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5536)
DOI
10.1200/JCO.2022.40.16_suppl.5536
Abstract #
5536
Poster Bd #
415
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.
First Author: Qin Xu
Poster
2021 ASCO Annual Meeting
Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.
First Author: Wei Wei
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results from the phase II study: Efficacy and safety of anlotinib plus sintilimab as second-line treatment for patients with advanced biliary tract cancers.
First Author: Shuiling Jin
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
First Author: Zhiwei Chang